Join us in Novo Nordisk Manufacturing

(1:29)

How a new Denmark tariff could impact Novo Nordisk

(2:49)

CEO DIALOGUE #35 - Lars Fruergaard Jørgensen, Novo Nordisk

(49:8)

Novo Nordisk (Ozempic)

(3:45:26)

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

(19:20)

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

(2:16)

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

(4:29)

How to use NovoPen 4

(6:46)

Novo Nordisk CEO on Catalent, Ozempic and Wegovy

(13:6)

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

(4:47)

Novo Nordisk shares sink on medicare price negotiation fears

(4:35)

Novo Nordisk CEO testifies before Senate on weight loss drug prices

(1:55)

Why Novo Nordisk's corporate structure stands out

(2:40)

Novo Nordisk CEO defends high price off Ozempic and Wegovy

(5:)

Life-changing careers at Novo Nordisk

(1:40)

'Attractive' growth ahead for Novo Nordisk, CEO says

(5:20)

Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market

(9:39)

Novo Nordisk is scaling Wegovy supply 'significantly': CFO

(6:48)